ARTICLE | Clinical News

VeriStrat regulatory update

March 10, 2014 7:00 AM UTC

Biodesix said it received CE Mark approval for VeriStrat to predict differential treatment outcomes between chemotherapy or Tarceva erlotinib for second-line, non-operable, advanced non-small cell lung cancer (NSCLC). The blood-based proteomic test identifies patients likely to benefit from EGFR inhibitors. Biodesix markets VeriStrat as a laboratory-developed test (LDT) in the U.S. to identify patients with advanced NSCLC who are likely to have good or poor outcomes after treatment with EGFR inhibitors. ...